research use only
Cat.No.S4485
|
In vitro |
DMSO
: 77 mg/mL
(199.25 mM)
Ethanol : 40 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 386.44 | Formula | C21H26N2O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 868049-49-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | BI 1744 | Smiles | COC1=CC=C(CC(C)(C)NCC(O)C2=C3OCC(=O)NC3=CC(=C2)O)C=C1 | ||
| Targets/IC50/Ki |
β2-adrenergic receptor
|
|---|---|
| In vivo |
The bronchoprotective half-life of abediterol in guinea pigs is 47 h for olodaterol. In anaesthetised dogs, this compound inhibits acetylcholine-induced bronchoconstriction, with ID40 (dose inhibiting bronchoconstriction by 40%) of 0.180 µg/kg. In parallel, effect on heart rate in dogs is measured, showing a safety index (defined as the ratio of the maximal dose without effect on heart rate and the ID40) of 10.5. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03030638 | Completed | Pulmonary Disease Chronic Obstructive |
Boehringer Ingelheim|RTI health solutions US |
February 8 2017 | -- |
| NCT02969317 | Completed | Pulmonary Disease Chronic Obstructive |
Boehringer Ingelheim |
February 24 2017 | Phase 1 |
| NCT02172118 | Completed | Healthy |
Boehringer Ingelheim |
August 2009 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.